New combo pill shows promise for stubborn leukemia
NCT ID NCT03578367
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to add asciminib, stay on imatinib alone, or switch to nilotinib. The goal was to see if the combination leads to better molecular responses at 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Georgia Regents University
Augusta, Georgia, 30912, United States
-
Novartis Investigative Site
Vienna, 1140, Austria
-
Novartis Investigative Site
Montreal, Quebec, H1T 2M4, Canada
-
Novartis Investigative Site
Brno, 625 00, Czechia
-
Novartis Investigative Site
Copenhagen, DK-2100, Denmark
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Krakow, 31 531, Poland
-
Novartis Investigative Site
Warsaw, 00-791, Poland
-
Novartis Investigative Site
Wroclaw, 50 367, Poland
-
Novartis Investigative Site
Lisbon, 1099-023, Portugal
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Moscow, 125167, Russia
-
Novartis Investigative Site
Moscow, 125284, Russia
-
Novartis Investigative Site
Saint Petersburg, 191024, Russia
-
Novartis Investigative Site
Saint Petersburg, 197341, Russia
-
Novartis Investigative Site
Uijeongbu-si, Gyeonggi-do, 11759, South Korea
-
Novartis Investigative Site
Seoul, 06591, South Korea
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Seville, 41009, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Changhua, 50006, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
-
Novartis Investigative Site
Liverpool, CH63 4JY, United Kingdom
-
Novartis Investigative Site
London, W12 0HS, United Kingdom
-
Novartis Investigative Site
Oxford, OX3 7LE, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
asciminib (ABL001) added to imatinib, compared to imatinib alone or nilotinib
What this could lead to
If it works, this could offer a new combination treatment to help CML patients who haven't reached very low levels of leukemia cells with standard therapy.
What could go wrong
This is a small, early-phase trial (104 people) with no long-term results yet. The added drug may cause more side effects or not improve outcomes significantly.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.